Home Blog Page 3389

GenScript Biotech and NSG Bio Form Strategic Partnership to Drive Biotechnology Innovation

SINGAPORE, April 23, 2025 /PRNewswire/ — GenScript Biotech Corporation, a global leader in biotechnology research services, and NSG Bio, Singapore’s premier biotech incubator, today announced a strategic partnership designed to accelerate innovation and growth within the biotechnology sector.

MoU signing ceremony between GenScript and NSG Bio
MoU signing ceremony between GenScript and NSG Bio

Through this partnership, GenScript will provide exclusive preferential rates along with technical guidance from experienced scientists across its extensive range of biotechnology services and products to NSG Bio residents. This initiative empowers startups and biotech firms within the NSG Bio community, facilitating easier access to state-of-the-art technologies and services, thereby enhancing innovation and speeding up the transition from research to commercialization.

Since its founding in 2019, NSG Bio has supported innovators in developing transformative solutions across health, biomedical, agrifood, and industrial biotechnology sectors. The incubator specializes in precision medicine, nucleic acid technologies, AI-driven drug discovery, synthetic biology, and other groundbreaking areas. With Singapore’s largest co-working biotech laboratory and office spaces and extensive networks of local and international partners, suppliers, and industry experts, NSG Bio has supported over 50 resident companies, fostering their growth and success.

“We are excited to partner with NSG Bio to bolster Singapore’s dynamic biotechnology ecosystem,” stated Dr. Janice Jin, President of GenScript Asia Pacific. “By extending preferential pricing and technical expertise to residents of NSG Bio, we aim to foster greater innovation among emerging biotechnology companies, allowing them to allocate more resources toward achieving scientific breakthroughs and market readiness.”

“NSG Bio is committed to fostering a thriving and world-class biotechnology ecosystem in Singapore. Our partnership with GenScript represents a significant step forward in enabling our resident companies to access cutting-edge scientific capabilities and industry expertise. By deepening collaboration between leading global service providers and local biotech innovators, we are helping to catalyze impactful scientific advancements and reinforce Singapore’s position as a global hub for biomedical innovation,” said Ms. Daphne Teo, Chairwoman of the Board & Founder of NSG Bio.

This partnership reflects a mutual commitment by both GenScript and NSG Bio to empowering biotechnology entrepreneurs and developing a vibrant and resilient biotechnology ecosystem.

About GenScript Biotech Corporation

Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. Guided by its mission to Make People and Nature Healthier Through Biotechnology, and its role as a trusted global leader, GenScript has a team of over 5,500 employees and has served more than 200,000 customers acrossover100 countries and regions.

Learn more here: https://www.genscript.com

About NSG Bio

Founded with a focus on supporting biotech innovation, NSG Bio offers state-of-the-art equipment, efficient operations, capital efficiency, the expertise of world-class teams and global networks to assist life sciences companies. The conducive R&D environment contains fully equipped, certified BSL-2 laboratory and office infrastructure across 70,000 sq ft in the prime location of Biopolis and Science Park in Singapore. By providing access to high-quality infrastructure, its extensive partner network, community, and value-add benefits, NSG Bio ensures that companies, ranging from emerging biotech startups to multinational companies, can rapidly and efficiently execute on their cutting-edge research and development ecosystem in Singapore, leading to the innovation of revolutionary technologies and products that translate into breakthrough biotech ventures and impact for patients.

For more information, visit www.nsgbio.com

CONTACT:
Hasyim Sim
hasyim.sim@nsgbio.com

 

project44 Expands Cross-Border Visibility for Over-the-Road Shipments Between China and Vietnam

In an industry first, project44 compliantly connects real-time data across borders—empowering multinational corporations to navigate shifting trade dynamics.

CHICAGO, April 23, 2025 /PRNewswire/ — project44 today announced it successfully provided visibility for its first full-truckload shipment between China and Vietnam. This industry-first achievement unlocks significant new business opportunities and supply chain efficiencies for multinational corporations operating across the Asia-Pacific region—particularly as China and Vietnam rapidly expand bilateral trade in response to new tariffs.

Over-the-road (OTR) transportation is the dominant freight mode in Vietnam, now accounting for 77% of the country’s freight volume However, medium-to-low technology adoption among local carriers has historically limited visibility into cross-border movements. With bilateral trade between China and Vietnam reaching a record $205 billion USD in 2024 and manufacturing investments accelerating in Vietnam, enhanced transportation connectivity between these two nations is critical for organizations adapting to evolving tariff landscapes.

project44 is uniquely authorized as the only real-time visibility provider permitted to transfer logistics data cross-border from China. Working closely with the Lingang Special Area, project44 ensures its Movement by project44™ platform delivers secure, compliant, and seamless visibility into China-based supply chains. Building upon its China capabilities, project44 now integrates real-time GPS and electronic logging device (ELD) data from Vietnam with its existing China OTR visibility data. This unprecedented integration overcomes long-standing technology barriers, enabling cross-border visibility and empowering organizations to confidently seize emerging trade opportunities.

“As the multinational brands we partner with navigate fast-changing global trade dynamics, we’re committed to equipping them with supply chain resilience and agility,” said Jett McCandless, Founder and CEO of project44. “project44’s extensive partner network and advanced technology uniquely position us to break down connectivity barriers and accelerate cross-border trade.”

“Cross-border visibility is critical for maintaining efficiency in today’s dynamic logistics landscape,” said Antonio Pacciolla, Ground & Rail Leader IMECA & APAC at CEVA Logistics. “As trade between key markets continues to grow, especially in our Asia Pacific region, CEVA Logistics relies on our partners’ solutions to seamlessly coordinate operations across borders. By integrating real-time data from multiple regions with the support of project44, CEVA is able to improve supply chain performance, ensure reliability and meet the increasing demands of global trade.”

To learn more, request a demo here

About project44    
project44 is on a mission to make supply chains work. project44’s Movement AI platform enables shippers, LSPs and carriers across the globe to reduce costs, optimize operations, deliver an exceptional customer experience and drive greater resiliency and sustainability. Having built the industry’s largest and most connected ecosystem, project44 provides visibility into over 1 billion shipments annually for over 1,000 of the world’s leading brands within manufacturing, automotive, retail, life sciences, food & beverage, CPG, and oil, chemical & gas. Learn more at project44.com.

Media contact:

press@project44.com

 

Cathay United Bank Crowned Best Bank for Sustainable Finance for Outstanding ESG Achievements

TAIPEI, April 23, 2025 /PRNewswire/ — Cathay United Bank, a longstanding advocate for energy transition, was recently crowned Best Bank for Sustainable Finance at the ESG Investing Awards by Global Markets Media. The Bank outperformed prominent global contenders such as Morgan Stanley, TD Bank Group, and the Bank of Nova Scotia, to be named the winner – the only Asian enterprise to claim such a title!

Cathay United Bank is a longstanding supporter of Earth Day, and was recently named Best Bank for Sustainable Finance.
Cathay United Bank is a longstanding supporter of Earth Day, and was recently named Best Bank for Sustainable Finance.

As the top sustainable finance brand in Taiwan, Cathay United Bank bases its energy transition policy on the Low-Carbon Economic Blueprint and the Environmental Sustainability Blueprint – covering Scope 1 to 3 emissions and the use of renewable energy – fully supporting Earth Day’s 2025 theme: “Our Power, Our Planet”. In addition to being the first in Taiwan’s financial sector to complete the energy transition of its head office in 2022, the Bank has been paving the way toward sustainability, providing financial solutions to all customers and stakeholders in pursuit of net zero.

Cathay United Bank noted that instead of viewing sustainable transition as a risk, it should be regarded as a positive force that drives business growth and transformation, while enhancing the risk resilience of businesses. The Bank introduced several innovations during its commitment to sustainable development, such as promoting internal carbon pricing for internal energy transition, and empowering employees to engage in their companies’ transition through sustainability performance-linked payroll services. With many companies inspired, the Bank is increasingly focused on transition strategies in its planning, aiming to create mutually beneficial long-term value for stakeholders.

To share experiences and explore solutions for sustainable transition with its partners, Cathay United Bank has established diverse collaboration models. For example, the Bank teamed up with the CDP, an international non-profit organization that helps companies disclose their environmental impact, to assist customers in understanding the importance of net zero and impact management. In 2024, thanks to the efforts of experts and the Bank’s staff, 121 among 150 companies invited by the Bank successfully obtained CDP scores, with the response rate of the CDP questionnaire exceeding 80 percent – landing high above the global supply chain’s average of 50 percent. The Bank also held forums and workshops with reputed organizations to share knowledge on achieving sustainable transition.

Furthermore, Cathay United Bank engaged with the Metal Industries Research and Development Centre, Taiwan’s first carbon footprint verification agency, to accelerate net zero transition by offering businesses transition technologies. The Bank has also created engagement models tailored to customers’ industry type, business scale, carbon emission level, and ESG development progress, aiming to enhance the customers’ ability to implement net zero transition. At the same time, the Bank continues to provide sustainability-linked loans, green deposits, sustainability performance-linked payroll services, and sustainable finance partnerships with small and medium enterprises. By offering technical and capital support, the Bank assists customers in achieving their sustainability goals.

Aside from achieving PAS 2060 certification for its head office and three green branches in 2024, Cathay United Bank further exemplified its role as a “green” landlord by signing a Corporate Power Purchase Agreement (CPPA). This CPPA offers lessees with the option of renewable energy and marks a step further towards achieving sustainability. Looking ahead, the Bank remains committed to the idea of “Our Power, Our Planet”, and aspires to wield its influence to bring together employees, customers, and stakeholders in the pursuit of net zero – building a sustainable tomorrow.

THE KORE IMPACT SET TO INTRODUCE INNOVATIVE KOREAN “GONGGU” CONCEPT TO US CREATORS AT EXCLUSIVE LA EVENT

BEVERLY HILLS, Calif., April 23, 2025 /PRNewswire/ — The Kore Impact Inc., a pioneering marketing company headquartered in Beverly Hills, is set to revolutionize the US e-commerce landscape with the introduction of “gonggu,” an innovative Korean group purchasing concept. The company will host an exclusive event for 100 creators in the Los Angeles area to showcase this unique marketing approach and to preview Korean products soon to be available in the American market.

The invite-only event will offer influential content creators a first look at The Kore Impact’s groundbreaking platform, Keverything, scheduled to launch on May 24th, 2025.This platform aims to connect US consumers with a portfolio of Korean products through a strategic network of influencer partnerships.

At the heart of The Kore Impact is a bold and visionary mission: to spark a cultural movement through commerce. Keverything isn’t just a shopping platform—it’s a curated gateway into the soul of Korea. From the electrifying energy of K-pop, the storytelling magic of K-dramas and K-movies, to the bold creativity of K-Art. Let’s not forget about the advanced technology of K-Skincare, the world-renowned excellence of K-Medical and K-Plastic Surgery, and the unforgettable experiences of K-Tourism—every offering being designed to inspire, connect, and elevate.

For Gen Z and Millennials in the U.S., this is more than a transaction—it’s an invitation to explore identity, culture, and innovation in one immersive experience. It’s where style meets substance, culture meets commerce, and passion meets greater possibilities.

Gonggu represents a transformative approach to group purchasing that maximizes reach while minimizing costs for both brands and consumers,” says Claudia Choi, CEO of The Kore Impact. “By bringing this concept to the US market, we’re creating an exciting opportunity for American creators to introduce their audiences to high-quality Korean products through a unique, community-driven shopping experience.”

The Kore Impact is actively building a global network of over 500,000 influencers who will collaborate through the Keverything platform to promote limited-time product campaigns using the gonggu model. This strategy has proven highly successful in the Korean market and is poised to capitalize on the growing popularity of K-culture in the United States.

The company’s goal is clear: to promote the Korean Wave (“Hallyu”) in the US and spark genuine connections between Korean brands and American consumers through the power of trusted creator voices. The upcoming LA event marks a major milestone in positioning gonggu as a revolutionary force in American e-commerce—and The Kore Impact as the bridge between the two cultures.

thekoreimpact.com

About The Kore Impact Inc.
The Kore Impact Inc. is an online marketing company based in Beverly Hills, California, dedicated to connecting Korean brands with US creators. Through the Keverything app, which is launching on May 24, 2025, the company introduces American consumers to premium Korean products via trusted influencer partnerships. With a mission to elevate K-culture and spark cross-cultural innovation, The Kore Impact is pioneering a new wave of commerce, driven by creativity, authenticity, and global connection.

 

DSC® Celebrates Earth Day With Tree Planting Participated by Nearly 1,000 Global Employees and Sustainable Material Innovation

PORTLAND, Ore., April 23, 2025 /PRNewswire/ — DSC®, a global leader in performance foam manufacturing, celebrates Earth Day from the ground up with its strong commitment to sustainable innovation,  waste and carbon emissions reduction, and reforestation efforts that contribute to a greener future. Today, DSC® launches another year of environmental stewardship with its annual tree planting initiative, nearly 1,000 employees around the globe are participating in this event, including in Vietnam, Indonesia, China, and U.S.

DSC® launches another year of environmental stewardship with its annual tree planting initiative. Nearly 1,000 DSC employees in Vietnam, Indonesia, China, and the U.S. are participating in the tree planting event.
DSC® launches another year of environmental stewardship with its annual tree planting initiative. Nearly 1,000 DSC employees in Vietnam, Indonesia, China, and the U.S. are participating in the tree planting event.

The initiative is part of DSC’s sustainability roadmap, Run the Relay – an ambitious plan powered by a zero-carbon, zero-waste mission. The long-term vision centers on reducing carbon emissions, cutting down waste, transitioning to renewable energy, fostering innovation, and employee engagement.

“We celebrate Earth Day today, but DSC® is committed to reducing our impact on the environment every day,” said Fennie Wei, COO of DSC®. “With sustainable materials and designing for a circular economy, we’re creating high-performance insoles that support a low-carbon future for both the planet and the people who wear them.”

Beyond its ongoing commitment to environmental sustainability, DSC® continues to lead the industry in material innovation, introducing bio-based alternatives that reduce dependency on fossil fuels. One of its most notable breakthroughs, DREAMCELL® XPRESSO, is a foam made with spent coffee grounds (SCG). This innovation not only enhances comfort and durability but also helps reduce landfill waste and greenhouse gas emissions. 

Another breakthrough supporting DSC®‘s vision of closed-loop manufacturing is DREAMCELL® ZERO – an insole made with 100% reused foam waste designed for comfort. By transforming foam waste into new products, DSC® takes a decisive step toward a circular economy in the footwear supply chain, closing the loop on waste, and creating a sustainable cycle of production and consumption.

Alongside its use of recycled or bio-based content, DSC® also pioneered the use of supercritical fluid foaming technology in large-scale insole production with its DURAPONTEX® N-Series. This method eliminates the use of harmful chemical blowing agents, and instead infusing nitrogen or carbon dioxide to create an innovative, high-performance foam. It creates ultra-lightweight insoles with evenly spaced microscopic bubbles and air pockets that offer superior cushioning and unmatched resilience.

For 80 years since its founding in 1945, Dahsheng Chemical (DSC®) has been a leader in foam innovation for the sports industries. Known for its premium comfort and performance foam DURAPONTEX® and DREAMCELL®, DSC® partners with top brands and footwear manufacturers worldwide. By advancing innovation and pushing the limits of foam manufacturing, DSC® is dedicated to creating eco-friendly and advanced foam solutions that set new standards in the industry.

Visit www.dahsheng.com to learn more about Dahsheng Chemical (DSC®) and its commitment to sustainability and eco-innovation.

Media Contact:
Erin Patterson
t: +1-323-422-0274
e: erin.patterson@writetheskycomms.com

 

Eyebright Medical Published its 2024 Environmental, Social and Governance Report

Commitment to Sustainable Development, Social Responsibility, and Corporate Governance

HONG KONG, April 23, 2025 /PRNewswire/ — Eyebright Medical Technology (Beijing) Co., Ltd. (“Eyebright Medical“, the “Company“, Stock Code: 688050.SH, together with its subsidiaries collectively known as the “Group“) is proud to announce that the Company has published its 2024 Environmental, Social and Governance Report.

Continuous Optimization of Core Profitability

During 2024, the Company reported revenue of RMB 1,410.02 million, a 48.24% increase compared to the prior year. Net profit attributable to shareholders was RMB 388.40 million, up 27.77% from the previous year. Excluding non-recurring items, net income reached RMB 390.08 million, reflecting a 35.08% increase. Basic earnings per share were RMB 2.05, highlighting Eyebright Medical’s strong performance and commitment to shareholder value.

Establishing a Cohesive Environmental Protection System with Diverse Energy-Saving Measures

Eyebright Medical prioritizes environmental protection by establishing a cohesive system that optimizes processes and upgrades facilities to meet strict standards, thereby enhancing governance.

In March 2025, the Company achieved ISO 14001 certification and actively promotes an energy management system while implementing various energy-saving initiatives, leading to ISO 50001 certification in February 2025. Certain production bases have also installed photovoltaic systems to harness solar energy, reducing reliance on non-renewable sources.

The “HiGenie” brand launched an “Empty Tube Recycling” program, encouraging sustainable consumption with no-threshold coupons for exchanging empty tubes. Eyebright’s commitment to sustainability is recognized by its inclusion in Beijing’s directory of water-saving enterprises for its innovations in water-saving technology and efficient resource utilization.

Advancing Global Collaboration and Employee Development While Upholding Social Responsibility and Health Standards

Eyebright Medical is dedicated to creating a global academic platform that integrates medical research with practice while supporting employee career development. During the Reporting Period, the company hosted 2 international exhibitions, 20 national conferences, and 70 regional meetings, attracting 2,783 online participants and 29,088 views. The Company has revised 2 state standards and 5 others, partnering with 5 universities and donating over RMB 1.2 million in materials to benefit 1,400 students.

Since 2022, Eyebright Medical has collaborated with 15 universities, contributing over RMB 4.5 million, providing 500 hours of training, and empowering over 2,500 students and 10,000 vision care professionals. The company established training bases at China Eye Valley, Tianjin Eye Hospital Vision Center, and its Beijing headquarters, conducting five sessions with 118 hours of instruction for over 200 participants. Its workforce comprises 57% female and 43% male employees, along with a balanced senior executive team.

To promote work-life balance, Eyebright Medical organizes initiatives like World Book Day, Sports Day, and outdoor activities. Prioritizing employee health, it achieved ISO 45001 certification in March 2025. The company is committed to international aid, grassroots healthcare, philanthropy, and scientific outreach, emphasizing its social responsibility and sustainable development goals.

Enhancing Governance and Transparency While Recognized for Shareholder Value and Quality Initiatives

Eyebright Medical is committed to optimizing governance by standardizing controls, protecting shareholder rights, and enhancing information security. The company has achieved an A-level disclosure rating from the Shanghai Exchange for 2 consecutive years, reflecting its dedication to corporate governance excellence.

During 2024, Eyebright Medical held 7 board meetings, approving 47 proposals, and 8 board committee meetings with 40 proposals approved. Additionally, it conducted 5 supervisory committee meetings and 1 shareholder meeting, leading to 11 proposals approved.

To improve quality and efficiency, Eyebright Medical launched its 2024 “Quality Improvement and Efficiency Enhancement for Returns” action plan, safeguarding investor rights through a share buyback of RMB 20.04 million and executive buy-ins of RMB 3.44 million. In March 2025, the Shanghai Stock Exchange recognized the Company as a model for shareholder value creation.

About Eyebright Medical

Eyebright Meical Technology (Beijing) Ltd (“Eyebright Medical”; SH Stock Code: 688050.SH) is a National High-tech Enterprise and state-level technologically advanced ‘little giant’ enterprises, located in Zhongguancun Science and Technology Park, Beijing, China.

The Company is an innovation-driven ophthalmic medical device manufacturer. Its balanced product portfolio spans three major areas of the ophthalmic field: cataract surgery, myopia management, as well as consumer vision care. Anchored by its three core product categories – intraocular lenses, orthokeratology lenses, and soft contact lenses – the company has strategically expanded its product pipeline to cover the full life cycle of eye health solutions. Eyebright Medical is striding into a world-leading medical enterprise on behalf of China’s ‘intelligent manufacturing’ power.

For more information about Eyebright Medical, please visit the official website of the Group: http://www.ebmedical.com/en/

Cohesity Automation Provides Faster, More Comprehensive Cyber Incident Response

Cohesity RecoveryAgent’s AI-powered Orchestration Makes Cyber Response and Recovery Easy so Customers Can Recover From Incidents Faster and With More Confidence 

SINGAPORE, April 23, 2025 /PRNewswire/ — Cohesity, the leader in AI-powered data security, today announced Cohesity RecoveryAgent, a new AI-powered cyber orchestration solution for Cohesity NetBackup and DataProtect customers. RecoveryAgent automates cyber recovery preparation, testing, compliance, and response, enabling customers to recover from cyber incidents faster. It offers intelligent, customizable recovery blueprints and enables rigorous testing of recovery processes in a non-production environment, giving customers more confidence in their ability to respond to proliferating cyberattacks.

Simplifying Cyber Recovery Through Automation and Intelligence
Modern IT environments are complex, comprising physical, virtual, and cloud-based systems. Responding to cyberattacks requires organizations to navigate this complexity while ensuring data integrity, availability, and regulatory compliance. RecoveryAgent addresses these challenges by generating customizable blueprints that automate recovery workflows, making cyber recovery response more efficient and adaptable.

With these customizable blueprints, organizations can better prepare for cyber incidents before they happen. RecoveryAgent’s intuitive UI allows teams to easily build recovery plans with scripted workflows that automatically integrate critical steps for incident response, such as threat hunting, malware scanning, and instant data restores. Users can rehearse recoveries to prove the blueprint will effectively recover their data in a non-production environment without impacting production applications. This frequent testing helps ensure readiness for real-world incidents.

RecoveryAgent’s Agentic AI capabilities allow recovery teams to:

  • Rapidly and easily create and edit recovery blueprints with AI assistance for automated testing of cyber impact or disaster recovery
  • Manage granular recovery across multiple domains in complex hybrid environments, including on-premises, cloud, PaaS, and containers
  • Speed up forensic investigations through automated threat scanning using native tools and best-in-class threat intelligence from Data Security Alliance partners
  • Have more confidence in a clean incident recovery with Agentic AI-powered intelligent recovery point recommendations and blast radius analysis of infected files across domains
  • Understand the real-world recovery times and how they align with the business SLAs
  • Ensure and demonstrate compliance with regulatory and business drivers by implementing standard recovery practices

“Every moment matters to customers experiencing a cyber incident. Having a comprehensive and thoroughly tested incident response plan can be the difference between minimal disruption and massive impact,” said Vasu Murthy, Chief Product Officer, Cohesity. “By simplifying and automating every step of the complex cyber recovery process, RecoveryAgent helps customers boost resilience and respond faster with more confidence to cyber incidents. The world’s largest organizations trust Cohesity because we understand the impact of cyber incidents and consistently offer new solutions like RecoveryAgent to help our customers be more confident in their cyber readiness and recovery.”

Seamless Integration for Enhanced Cyber Resilience
RecoveryAgent automates time-consuming and manual tasks such as vulnerability scanning, malware scanning, and data classification into a structured blueprint. It can also automate forensics investigation, configuration hardening, and patching when orchestrated on virtual machines that are recovered within the solution. These capabilities are powered by Cohesity’s Data Security Alliance, which integrates with leading security vendors to help security teams become more agile and productive. Additionally, RecoveryAgent enhances Cohesity’s existing clean room solution, making activation faster and more intuitive.  

“AntemetA has a complex technology infrastructure, and as a result, we need solutions developed with extensive field experience to enable us to be as effective as possible, especially as we are exposed to increasing amount of cyber risks,” said Stéphane Colin, CTO, AntemetA. “This is only possible with trusted partners who take time to understand our unique complexity and work with us to ensure our data can be recovered with confidence and our services guarantee the highest level of resilience, whatever cyber challenges we face. We have a longstanding partnership with Cohesity because it continues to develop solutions like RecoveryAgent, which help us deliver more relevant and effective services. That, in turn, has earned us an equally long-lasting trust from our customers.”

RecoveryAgent is the first new offering to emerge from the joint development efforts of Cohesity and Veritas since the companies came together in December. By combining the capabilities of NetBackup Recovery Blueprints and Recommended Recovery Points with AI-powered intelligence and innovation native to DataProtect, RecoveryAgent is an example of the rapid innovation enabled by integrating both companies’ technology. It also highlights Cohesity’s commitment to simplifying user experiences and enhancing customer confidence in cyber resilience strategies.

RecoveryAgent is currently available to select customers in Tech Preview and is expected to be generally available for NetBackup and DataProtect customers in the second half of the calendar year 2025.

For more information about Cohesity RecoveryAgent and how it can support your organization’s cybersecurity needs, watch our video. And for more insights on breach response and how to strengthen your organization’s resilience, watch our conversation.    

About Cohesity

Cohesity is the leader in AI-powered data security. Over 13,600 enterprise customers, including over 85 of the Fortune 100 and nearly 70% of the Global 500, rely on Cohesity to strengthen their resilience while providing Gen AI insights into their vast amounts of data. Formed from the combination of Cohesity with Veritas’ enterprise data protection business, the company’s solutions secure and protect data on-premises, in the cloud, and at the edge. Backed by NVIDIA, IBM, HPE, Cisco, AWS, Google Cloud, and others, Cohesity is headquartered in Santa Clara, CA, with offices around the globe. To learn more, follow Cohesity on LinkedIn, X, and Facebook.

Investment of Approx. USD 4.5 Million in Development of Diagnostics for Tuberculosis to Partners Including Fujirebio and University Hospital Heidelberg

TOKYO, April 23, 2025 /PRNewswire/ — The Global Health Innovative Technology (GHIT) Fund announced today an investment of approximately JPY 679 million (USD 4.5 million1) for the development of diagnostics for tuberculosis, in addition to an investment of approximately JPY 15.9 million (USD 0.1 million1) for a drug discovery project for Chagas disease and leishmaniasis.2 

Investment of approximately JPY 679 million (USD 4.5 million1) for the development of diagnostics for tuberculosis
Tuberculosis (TB) remains a serious infectious disease, with approximately 10.8 million cases and 1.25 million deaths reported in 2023, making it the leading causes of death from a single infectious agent.3 The United Nations’ Sustainable Development Goals (SDGs) set a target to end TB by 2030, but achieving this goal requires accurate and accessible diagnostic technologies. Current TB tests face challenges such as low sensitivity, high costs, complexity, and the need for specialized equipment and sputum samples, making them unsuitable for all patients. In particular, children, people with conditions who cannot produce sputum, and those in resource-limited settings often struggle to receive timely diagnoses, causing the continued spread of the disease. To address this issue, the GHIT Fund has decided to invest approximately JPY 679 million (USD 4.5 million1) towards a new TB diagnostic development project by US-based diagnostic developer Fluxus, Inc., 4 in partnership with Fujirebio, Inc., a developer of clinical diagnostics in Japan,4 and Heidelberg University Hospital in Germany.

This project will leverage Fluxus’ cutting-edge ultrasensitive detection technology to develop and validate a urine-based TB biomarker lipoarabinomannan (LAM) assay on its automated benchtop immunoassay analyzer. Additionally, the project will design and develop critical components for a portable, ultrasensitive point-of-care (PoC) system that integrates the urine LAM test. This advanced technology will enable rapid, accurate, and accessible diagnosis across a broader patient population, contributing to improved clinical outcomes and reduced transmission.

In addition, the GHIT Fund will invest approximately JPY 15.9 million (USD 0.1 million1) in a screening project against Chagas disease and leishmaniasis by Kitasato University, Nagasaki University, University of Tokyo, and Drugs for Neglected Diseases initiative (DNDi).

Please refer to Appendix 1 for detailed descriptions on these projects and their development stages.

As of March 31, 2025, the GHIT Fund has invested in 36 projects, including 15 discovery projects, 12 preclinical projects, and 9 clinical trials.5 The total amount of investments since 2013 is JPY 38.2 billion (USD 255 million1) (Appendix 2).

1 USD1 = JPY149.53, the approximate exchange rate on March 31, 2025.
2 These awarded projects were selected and approved as new investments from among proposals to RFP2023-002 and RFP2024-001 for the Product Development Platform and the Screening Platform, which were open for applications from June 2023 to July 2024.
3 WHO: https://www.who.int/news-room/fact-sheets/detail/tuberculosis
4
 Fluxus, Inc. and Fujirebio, Inc. are members of Fujirebio.
5 This number includes projects in the registration phase.

The GHIT Fund is a Japan-based international public-private partnership (PPP) fund that was formed between the Government of Japan, multiple pharmaceutical companies, the Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP). The GHIT Fund invests in and manages an R&D portfolio of development partnerships aimed at addressing neglected diseases, such as malaria, tuberculosis, and neglected tropical diseases, which afflict the world’s vulnerable and underserved populations. In collaboration with global partners, the GHIT Fund mobilizes Japanese industry, academia, and research institutes to create new drugs, vaccines, and diagnostics for malaria, tuberculosis, and neglected tropical diseases.
https://www.ghitfund.org/en

Appendix 1. Project Details

ID: G2023-204

Project Title

Ultrasensitive Detection of Urine LAM for Point-of-Care Rapid Diagnosis of All Forms
of Tuberculosis

Collaboration

Partners

1. Fluxus, Inc. (USA)

2. Fujirebio, Inc. (Japan)

3. Heidelberg University Hospital (Germany)

Disease

Tuberculosis

Intervention

Diagnostics

Stage

Product Design, Product development

Awarded Amount

JPY 679,783,110 (USD 4.54 million)

Status

New project

Summary

[Project objective]

To develop a prototype portable point-of-care (PoC) system and integrated ultrasensitive
assay for detection of Lipoarabinomannan (LAM) in urine. The test will be benchmarked
to a fully-validated ultrasensitive urine LAM assay being developed on Fluxus’
automated benchtop immunoassay analyzer.

 

[Project design]The project objectives will be achieved by performing the following Specific Aims: 1)
Complete development and validation of an ultrasensitive urine LAM assay on an
existing benchtop immunoassay analyzer. This essay will be adapted and transferred to a
stable and cost-effective PoC cartridge format. 2) Design and development of critical
components for a portable, ultrasensitive PoC system, with functional cartridge and prototype PoC LAM assay.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/240/en

ID: S2024-122

Project Title

Searching for Chagas disease therapeutic seed compounds from microbial cultures

Collaboration

Partners

1. Kitasato University (Japan)

2. Nagasaki University (Japan)

3. University of Tokyo (Japan)

4. Drugs for Neglected Diseases initiative (DNDi) (Switzerland)

Disease

Chagas disease / Leishmaniasis

Intervention

Drug

Stage

Screening

Awarded Amount

JPY 15,945,864 (USD 106,639)

Status

New project

Summary

[Project objective]

The main objective of our proposed project is to identify novel T. cruzi active scaffolds
meeting GHIT/DNDi hit criteria and amenable for further development by screening
microbial cultured broths with a natural product chemistry approach. We aim at
characterizing at least five T. new chemical templates unprecedently associated with T.
cruzi
activity over an 18-month work period. We will also opportunistically evaluate the
anti-Leishmania donovani activity of any antichagasic agent to be identified in the course
of the project.

 

[Project design]In this project, three academic institutions (Kitasato University, Nagasaki University, and
the University of Tokyo) and DNDi will utilize their expertise to identify at least five
seed compounds for Chagas disease therapeutics produced by microorganisms in a one-
and-a-half-year research period. The seed compounds for Chagas disease therapeutics to
be identified during the project will also be assessed for their activity against Leishmania
donovani
, which causes visceral leishmaniasis, to verify their drug potential.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/241/en

*All amounts are listed at an exchange rate of USD1 = JPY149.53, the approximate exchange rate on March 31, 2025.

Appendix 2. Investment Overview (as of March 31, 2025)

Investments to date
Total investments: 38.2 billion yen (USD 255 million1)
Total invested projects: 136 (36 active projects and 100 completed projects)

To learn more about the GHIT Fund’s investments, please visit
Investment Overview: https://www.ghitfund.org/investment/overview/en
Portfolio: https://www.ghitfund.org/investment/portfolio/en
Advancing Portfolio: https://www.ghitfund.org/investment/advancingportfolio/en
Clinical Candidates: https://www.ghitfund.org/investment/clinicalcandidates/en 

For more information, contact:
Katy Lenard at +1-301-280-5719 or klenard@burness.com
Mina Ohata at +81-36441-2032 or mina.ohata@ghitfund.org